INSPIREMD INC. - COMMON STOCK

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

26 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

06 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

28 Feb 2024 06:00:00 By Nasdaq GlobeNewswire

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

12 Feb 2024 06:00:00 By Nasdaq GlobeNewswire

InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework

31 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

03 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System

20 Dec 2023 06:00:00 By Nasdaq GlobeNewswire

InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

27 Nov 2023 06:00:00 By Nasdaq GlobeNewswire

InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update

06 Nov 2023 06:00:00 By Nasdaq GlobeNewswire

InspireMD to Participate in Upcoming November Investor Conferences

02 Nov 2023 07:00:01 By Nasdaq GlobeNewswire

InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23

01 Nov 2023 13:19:15 By Nasdaq GlobeNewswire

InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th

30 Oct 2023 08:21:50 By Nasdaq GlobeNewswire

InspireMD Supports CMS’ Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients

12 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives

03 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23

31 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update

08 Aug 2023 06:00:01 By Nasdaq GlobeNewswire

InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial

26 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

InspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

18 May 2023 07:00:01 By Nasdaq GlobeNewswire

InspireMD Reports First Quarter 2023 Financial Results and Provides Business Update

16 May 2023 06:00:01 By Nasdaq GlobeNewswire

InspireMD Announces Private Placement of Up to $113.6 Million

15 May 2023 07:00:01 By Nasdaq GlobeNewswire